Δ9-tetrahydrocannabinol

Neuroprotectant (moderate), N/A, The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

Neuroprotectant (major), N/A, The potential therapeutic effects of THC on Alzheimer’s disease

Neuroprotectant (minor), 4.5mg, Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial

Neuroprotectant (moderate), Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.

Neuroprotectant (major),The potential therapeutic effects of THC on Alzheimer’s disease

Analgesic (minor), 10mg, Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

Antiglaucoma (moderate), 2.7mg,  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

Antiglaucoma (moderate), N/A, A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

Appetite Stimulant (moderate), 2.5mg A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia

Appetite Stimulant (moderate), 2.5 mg, A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia

Appetite Stimulant (moderate), N/A, A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa

Bronchodilating activity (moderate), 20mg, Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects

Bronchodilating activity (moderate), 200mg, Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients

Bronchodilating activity (moderate), 500mg, Effects of smoked marijuana in experimentally induced asthma

Antiinflammatory (minor), Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study

Neuroprotective (moderate),3mg, Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial

NAAntiinflammatory (minor), N/A, Antipyretic, analgesic and anti-inflammatory effects of Δ9-tetrahydrocannabinol in the rat

Antiemetic (major), N/A, Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis

Antiemetic (major), 5mg,10mg,15mg, Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications

Antiemetic (minor), N/A, THC or Compazine for the cancer chemotherapy patient–the UCLA study. Part II: Patient drug preference

Antiemetic (moderate), N/A, The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy

Antiemetic (moderate), N/A, A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy

Antiemetic (moderate), N/A, Comparative trial of the antiemetic effects of THC and haloperidol

Antiemetic (moderate), N/A, Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy

Antiemetic (moderate), N/A, Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine

Antiemetic (moderate), N/A, Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (Dronabinol)

Antiemetic (moderate), N/A, Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo

Antiemetic (moderate), N/A, Regulation of nausea and vomiting by cannabinoids

Antiemetic (moderate), N/A, Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine

Antiemetic (moderate), 5.0ng/mL,5.0 to 10.0ng/mL,10.0ng/mL plasma

Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation

Antiemetic (moderate), d8-THC, 18mg/m2, An efficient new cannabinoid antiemetic in pediatric oncology

Antiemetic (moderate), d9-THC, 18mg/m2, Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy

Antiemetic (moderate),d9-THC, 10mg/m2, Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study

Antiemetic (moderate), d9-THC, 15mg, Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting

Antileukemic (major), 200mg/kg, Antineoplastic Activity of Cannabinoids

Glaucoma is a group of eye diseases which result in damage to the optic nerve and cause vision loss., Glaucoma

Antiglaucoma (minor),N/A, Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma

Antiglaucoma (minor), 12mg, Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon?

Antiglaucoma (minor), 0.4% mixture Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy
Antiglaucoma (minor), 2.8% mixture, Effects of tetrahydrocannabinol on arterial and intraocular hypertension

Anticancer (major), N/A, A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

Antitumor (moderate), N/A, A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

Appetite Stimulant (moderate), A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men

Antiinflammatory (moderate), N/A, Chronic Administration of Δ9-Tetrahydrocannabinol Induces Intestinal Anti-Inflammatory MicroRNA Expression during Acute Simian Immunodeficiency Virus Infection of Rhesus Macaques

Analgesic (moderate), 10mg, A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

Antiemetic  (moderate), 15mg/m2, Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

Antinociceptive (moderate), N/A, Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis

Antispasticity (moderate), N/A, Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

Antispasticity (moderate), N/A, The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity

Antispasticity (moderate), N/A, Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

Antispasticity (moderate), N/A, Safety, tolerability, and efficacy of orally administered cannabinoids in MS

Antispasticity (moderate) N/A, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

Antispasticity (moderate), 10-15mg, 2.5-5mg, The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients

Antispasticity (moderate), 7.5mg, Delta-9-THC in the treatment of spasticity associated with multiple sclerosis

Antispasticity (moderate), 4 sprays, Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity

Antispasticity (moderate), 33% of mixture, The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)

Antispasticity (moderate), 2-10 inhalations, Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Antispasticity (moderate), 1.54% of mixture, Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers

Antitremor (moderate) N/A, Tetrahydrocannabinol for tremor in multiple sclerosis

Improve neurogenic symptoms (moderate) (moderate), 2.5–120mg, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

Urinary Protection (moderate) 2.5mg, An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

Antiemetic (moderate), 8.4mg,16.9mg, Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac

Antiemetic (moderate), N/A, Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol

Neuroprotectant (moderate), N/A, Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants

Analgesic (minor), 0.022mg/kg, 0.044mg/kg, Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response

Analgesic (minor), N/A, An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics

Analgesic (minor), 2.5–15mg, Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

Analgesic (minor), 6.7% of mixture, 2.9% of mixture, A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis

Analgesic (minor), 20mg, The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions

Analgesic (minor), N/A, Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice

Analgesic (minor), 5mg, Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain

Analgesic (minor), N/A, Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain

Analgesic (minor), N/A, An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics

Analgesic (minor), N/A, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-Related Pain

Analgesic (minor), N/A, A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

Analgesic (minor), 8 mg,Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability

Analgesic (minor), 12.3ng/mL/mg,  The analgesic properties of delta-9-tetrahydrocannabinol and codeine

Analgesic (minor), 10mg, 20mg, The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study

Analgesic (minor), 5mg, Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine

Analgesic (minor), 2mg, Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies

Analgesic (minor), 20mg, Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers

Analgesic (minor), 5mg, Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial

Antinociceptive (moderate), 1mg/kg,5mg/kg, Dopamine D2 receptor antagonists prevent Δ9-tetrahydrocannabinol-induced antinociception in rats

Antinociceptive (moderate), 4mg/kg, Low dose combination of morphine and Δ9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors

Antidepressant (moderate), 5mg, Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder

Anxiolytic (moderate), N/A, Cannabinoid facilitation of fear extinction memory recall in humans

Antipsychotic (moderate), 2.5mg, 5mg, Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction

Improves sleep (moderate), 20mg, Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers

Antihyperactivity (moderate), N/A, Oral Delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report

Antihyperactivity (moderate), 10mg, Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial

Antihyperactivity (moderate), 10mg, Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol

Antigastroesophageal reflux (moderate), 20 mg, Effect of Delta(9)-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans

Neuroprotective (moderate), N/A, Effect of marijuana use on outcomes in traumatic brain injury